Zydus Lifesciences Share Price
Sector: Biotechnology & Drugs
982.45 -5.65 (-0.57%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
978.05
Today’s High
994.95
52 Week Low
482.55
52 Week High
1031.3
983.95 -4.05 (-0.41%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
978.3
Today’s High
994.9
52 Week Low
484.95
52 Week High
1031.7
Key Metrics
- Market Cap (In Cr) 99415.92
- Beta 0.38
- Div. Yield (%) 0.61
- P/B 5.71
- TTM P/E 23.57
- Peg Ratio 1.34
- Sector P/E 31.46
- D/E -
- Open Price 989.2
- Prev Close 988.1
Zydus Lifesciences Analysis
Price Analysis
-
1 Week5.84%
-
3 Months30.08%
-
6 Month70.99%
-
YTD43.35%
-
1 Year89.73%
Risk Meter
- 27% Low risk
- 27% Moderate risk
- 27% Balanced Risk
- 27% High risk
- 27% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 6
- Buy
- 6
- 6
- 6
- 7
- Hold
- 9
- 9
- 9
- 11
- Sell
- 3
- 3
- 3
- 3
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 27
- 27
- 27
- 29
Zydus Lifesciences News
Stocks to Watch: Bajaj Finance, Yes bank, Wipro, Coforge, Titan, Adani Green
8 min read . 08:08 AM ISTVodafone Idea, Nykaa, SAIL may enter MSCI Global Standard index in August rejig
2 min read . 30 Apr 2024Stocks to Watch: BHEL, IDFC First Bank, Dr. Reddy's, REC, Chalet Hotels, Alkem
4 min read . 28 Mar 2024Buy or sell: Sagar Doshi of Nuvama recommends buying these three stocks today
4 min read . 27 Mar 2024Zydus Lifesciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2023
- Total Revenue
- 17237.4
- Selling/ General/ Admin Expenses Total
- 6263.3
- Depreciation/ Amortization
- 722.7
- Other Operating Expenses Total
- 342.3
- Total Operating Expense
- 14988.8
- Operating Income
- 2248.6
- Net Income Before Taxes
- 2589.7
- Net Income
- 1960.3
- Diluted Normalized EPS
- 23.79
- Period
- 2023
- Total Assets
- 25756.4
- Total Liabilities
- 8240.6
- Total Equity
- 17515.8
- Tangible Book Valueper Share Common Eq
- 114.81
- Period
- 2023
- Cashfrom Operating Activities
- 2688.8
- Cashfrom Investing Activities
- 1171.2
- Cashfrom Financing Activities
- -4400.4
- Net Changein Cash
- -533.8
- Period
- 2022
- Total Revenue
- 15109.9
- Selling/ General/ Admin Expenses Total
- 5385.9
- Depreciation/ Amortization
- 713
- Other Operating Expenses Total
- 288.4
- Total Operating Expense
- 12523.1
- Operating Income
- 2586.8
- Net Income Before Taxes
- 2838.1
- Net Income
- 4487.3
- Diluted Normalized EPS
- 21.01
- Period
- 2022
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021
- Total Revenue
- 14403.5
- Selling/ General/ Admin Expenses Total
- 5254.6
- Depreciation/ Amortization
- 669.6
- Other Operating Expenses Total
- 301
- Total Operating Expense
- 11873
- Operating Income
- 2530.5
- Net Income Before Taxes
- 2399.2
- Net Income
- 2133.6
- Diluted Normalized EPS
- 23.38
- Period
- 2021
- Total Assets
- 23884.7
- Total Liabilities
- 10892.4
- Total Equity
- 12992.3
- Tangible Book Valueper Share Common Eq
- 62.61
- Period
- 2021
- Cashfrom Operating Activities
- 3185.1
- Cashfrom Investing Activities
- -722.5
- Cashfrom Financing Activities
- -2548.9
- Net Changein Cash
- -90.5
- Period
- 2020
- Total Revenue
- 14253.1
- Selling/ General/ Admin Expenses Total
- 5142.8
- Depreciation/ Amortization
- 696.5
- Other Operating Expenses Total
- 804.3
- Total Operating Expense
- 12515.1
- Operating Income
- 1738
- Net Income Before Taxes
- 1495.4
- Net Income
- 1176.6
- Diluted Normalized EPS
- 14.4
- Period
- 2020
- Total Assets
- 23686.6
- Total Liabilities
- 13310.9
- Total Equity
- 10375.7
- Tangible Book Valueper Share Common Eq
- 35.14
- Period
- 2020
- Cashfrom Operating Activities
- 2505.4
- Cashfrom Investing Activities
- -1012.3
- Cashfrom Financing Activities
- -1094.2
- Net Changein Cash
- 398.9
- Period
- 2019
- Total Revenue
- 13165.6
- Selling/ General/ Admin Expenses Total
- 4287.6
- Depreciation/ Amortization
- 598.6
- Other Operating Expenses Total
- 592.2
- Total Operating Expense
- 10783.4
- Operating Income
- 2382.2
- Net Income Before Taxes
- 2382.1
- Net Income
- 1848.8
- Diluted Normalized EPS
- 18.12
- Period
- 2019
- Total Assets
- 23483.1
- Total Liabilities
- 13096.8
- Total Equity
- 10386.3
- Tangible Book Valueper Share Common Eq
- 32.51
- Period
- 2019
- Cashfrom Operating Activities
- 1543.2
- Cashfrom Investing Activities
- -4238.7
- Cashfrom Financing Activities
- 1884.6
- Net Changein Cash
- -810.9
- Period
- 2018
- Total Revenue
- 11954.4
- Selling/ General/ Admin Expenses Total
- 3850
- Depreciation/ Amortization
- 538.8
- Other Operating Expenses Total
- 467
- Total Operating Expense
- 9643.4
- Operating Income
- 2311
- Net Income Before Taxes
- 2330.8
- Net Income
- 1775.8
- Diluted Normalized EPS
- 17.65
- Period
- 2018
- Total Assets
- 18065.3
- Total Liabilities
- 9320.8
- Total Equity
- 8744.5
- Tangible Book Valueper Share Common Eq
- 59.37
- Period
- 2018
- Cashfrom Operating Activities
- 919.3
- Cashfrom Investing Activities
- -973.7
- Cashfrom Financing Activities
- 51.5
- Net Changein Cash
- -2.9
- Period
- 2023-12-31
- Total Revenue
- 4505.2
- Selling/ General/ Admin Expenses Total
- 817.3
- Depreciation/ Amortization
- 194.8
- Other Operating Expenses Total
- 1137.6
- Total Operating Expense
- 3618.2
- Operating Income
- 887
- Net Income Before Taxes
- 925.5
- Net Income
- 789.6
- Diluted Normalized EPS
- 7.58
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 4368.8
- Selling/ General/ Admin Expenses Total
- 752.9
- Depreciation/ Amortization
- 184.2
- Other Operating Expenses Total
- 1078.2
- Total Operating Expense
- 3489.1
- Operating Income
- 879.7
- Net Income Before Taxes
- 1007.2
- Net Income
- 800.7
- Diluted Normalized EPS
- 7.92
- Period
- 2023-09-30
- Total Assets
- 25879.4
- Total Liabilities
- 7146.6
- Total Equity
- 18732.8
- Tangible Book Valueper Share Common Eq
- 127.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 2212.9
- Cashfrom Investing Activities
- -709.3
- Cashfrom Financing Activities
- -1645.1
- Net Changein Cash
- -141.5
- Period
- 2023-06-30
- Total Revenue
- 5139.6
- Selling/ General/ Admin Expenses Total
- 730.4
- Depreciation/ Amortization
- 179.8
- Other Operating Expenses Total
- 1202.4
- Total Operating Expense
- 3801.2
- Operating Income
- 1338.4
- Net Income Before Taxes
- 1329.2
- Net Income
- 1086.9
- Diluted Normalized EPS
- 10.87
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 4667.7
- Selling/ General/ Admin Expenses Total
- 723.9
- Depreciation/ Amortization
- 178.6
- Other Operating Expenses Total
- 1276.6
- Total Operating Expense
- 4476.4
- Operating Income
- 191.3
- Net Income Before Taxes
- 485.8
- Net Income
- 296.6
- Diluted Normalized EPS
- 7.22
- Period
- 2023-03-31
- Total Assets
- 25756.4
- Total Liabilities
- 8240.6
- Total Equity
- 17515.8
- Tangible Book Valueper Share Common Eq
- 114.81
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2688.8
- Cashfrom Investing Activities
- 1171.2
- Cashfrom Financing Activities
- -4400.4
- Net Changein Cash
- -533.8
- Period
- 2022-12-31
- Total Revenue
- 4362.3
- Selling/ General/ Admin Expenses Total
- 689
- Depreciation/ Amortization
- 181.6
- Other Operating Expenses Total
- 1206.9
- Total Operating Expense
- 3587.9
- Operating Income
- 774.4
- Net Income Before Taxes
- 780.1
- Net Income
- 622.9
- Diluted Normalized EPS
- 6.15
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Zydus Lifesciences Technical
Moving Average
SMA
- 5 Day946.43
- 10 Day950.4
- 20 Day974.27
- 50 Day950.91
- 100 Day825.22
- 300 Day722.24
Zydus Lifesciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Divis Laboratories
- 3965.25
- 1.2
- 0.03
- 4104
- 3050.15
- 105264.93
- Dr Reddys Laboratories
- 6322.8
- 34.5
- 0.55
- 6505.5
- 4383.4
- 105057.58
- Zydus Lifesciences
- 982.45
- -5.65
- -0.57
- 1031.3
- 482.55
- 99444
- Torrent Pharmaceuticals
- 2774.1
- 100.3
- 3.75
- 2745.55
- 1599
- 93888.15
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40450.12
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Divis Laboratories
- 58.24
- 8.32
- 21.28
- 27.9
- Dr Reddys Laboratories
- 22.2
- 4.43
- 14.9
- 12.76
- Zydus Lifesciences
- 40.09
- 5.51
- 14.77
- 12.89
- Torrent Pharmaceuticals
- 72.49
- 14.43
- 17.51
- 11.22
- Lupin
- 170.32
- 6.01
- 0.35
- 0.37
Zydus Lifesciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-Feb-24
- Quarterly Results & Buy Back of shares
- 07-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 18-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 20-May-22
- Audited Results, Dividend & Buy Back
- 03-Feb-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 11-Aug-23
- 18-May-23
- AGM
- 10-Aug-22
- 21-May-22
- AGM
- 18-Feb-22
- 25-Jan-22
- EGM
- 11-Aug-21
- 27-May-21
- AGM
- 11-Jun-21
- 18-May-21
- EGM
- -
- 20-May-22
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 18-May-23
- 28-Jul-23
- 28-Jul-23
- 6
- 20-May-22
- 29-Jul-22
- 28-Jul-22
- 2.5
- 27-May-21
- -
- 28-Jul-21
- 3.5
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)